BioSpace News Archive

Sanofi announced the completion of its acquisition of Provention Bio, Inc. The acquisition adds TZIELD, an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.

Jaguar Health, Inc. announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs.

Teva Pharmaceutical Industries Ltd. announced that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities.

CNS Pharmaceuticals, Inc. today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET.

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (Stimulated Tumor-Cells) Technology Platform.

Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases.

Actinium Pharmaceuticals, Inc. today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting that was held in Paris, France April 23 – 26, 2023.

Defence Therapeutics Inc. (CSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®.

Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announced they have entered a research and development collaboration.

Almaden Genomics has updated its g.nome platform to integrate with Jupyter Notebook, allowing bioinformaticians and data scientists to leverage the cloud-native platform’s genomic workflows in the environment and programming language they are most familiar with.